Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) VP Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical stock in a transaction on Friday, December 1st. The stock was sold at an average price of $21.99, for a total transaction of $109,950.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Kimberly Gentile also recently made the following trade(s):

  • On Wednesday, November 1st, Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $29.28, for a total transaction of $146,400.00.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) traded down $0.08 on Tuesday, hitting $21.10. 532,300 shares of the stock traded hands, compared to its average volume of 216,377. Biohaven Pharmaceutical Holding Co Ltd has a one year low of $17.00 and a one year high of $39.51.

BHVN has been the topic of several analyst reports. Zacks Investment Research downgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. BidaskClub raised shares of Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $54.00 price target on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 price target (up previously from $30.00) on shares of Biohaven Pharmaceutical in a research note on Wednesday, September 13th. Finally, Morgan Stanley lifted their price target on shares of Biohaven Pharmaceutical from $28.00 to $47.00 and gave the stock an “overweight” rating in a research note on Monday, September 25th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $38.17.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deschutes Portfolio Strategy LLC bought a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth about $374,000. Strs Ohio bought a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth about $680,000. Artal Group S.A. bought a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth about $1,869,000. Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth about $2,790,000. Finally, Alps Advisors Inc. bought a new stake in shares of Biohaven Pharmaceutical in the 3rd quarter worth about $1,316,000. 47.76% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) VP Sells $109,950.00 in Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/05/biohaven-pharmaceutical-holding-co-ltd-bhvn-vp-sells-109950-00-in-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.